In a shock move, AstraZeneca has ditched a plan to invest £450 million ($558 million) in a new vaccine manufacturing plant in ...

Detailed price information for Meta Platforms Inc (META-Q) from The Globe and Mail including charting and trades.

“In 2025, we are poised to diversify our business further across multiple dimensions: our revenue, as we continue the launches of CASGEVY, ALYFTREK and potentially ... on the study design and ...

It will take time for revenue to grow since Casgevy requires a months-long treatment ... And the compensation packages, which will somewhat weigh on CrowdStrike growth in the near term, over ...

In fact, this approval of Casgevy for blood disorders represented ... offered companies compensation packages, and made moves to ensure a similar event doesn't happen again. The company said ...

The deal is notable because the U.K.’s cost-effectiveness watchdog initially raised concerns about the durability of the treatment, called Casgevy, in a preliminary ruling last year, saying it ...

Vertex and partner CRISPR Therapeutics’ CRSP one-shot gene therapy Casgevy was approved for two blood disorders, sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), in ...

Prof Bola Owolabi, of NHS England, called it a "monumental step forward", and said the one-off treatment Casgevy, also known as Exa-cel, "holds a very real prospect of a cure". A confidential ...

“Building on the success of CASGEVY’s launch, we continue to broaden our portfolio across oncology, autoimmune and cardiometabolic indications. 2025 promises to be a milestone-rich ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

Vertex offers up to $70,000 in fertility services assistance for patients undergoing Casgevy treatment. HHS claims Vertex’s program incentivizes patients to choose its gene therapy over competitors.